ArticlePathogens (Basel, Switzerland)2020
In Silico Design and Validation of OvMANE1, a Chimeric Antigen for Human Onchocerciasis Diagnosis.
Article in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- In Silico Design and Computational Characterization of Novel Chimeric Multiepitope Antigens for Mpox Serosurveillance: An Immunoinformatics Approach.Health science reports · 2026Article
- Safety and immunogenicity of an adjuvanted human onchocerciasis vaccine candidate,Clinical & translational immunology · 2026Article
- In silico design and validation of a Plasmodium falciparum multi-epitope diagnostic antigen (PfMEDA1) for the diagnosis of falciparum malaria.BMC infectious diseases · 2025Article
- Preliminary Evaluation of the Diagnostic Performance of OvMANE1 and OvMCBL02 Multiepitope Antigens for the Non-Invasive Diagnosis of Onchocerciasis Exposure.Life (Basel, Switzerland) · 2025Article
- An Antibody Biomarker Associated with Onchocerca volvulus Microfilariae Identified by Proteomic Analysis of Parasite Tissues Isolated from Paraffin Embedded O. volvulus Nodules by Laser Capture Microdissection.The American journal of tropical medicine and hygiene · 2025Article
- Leveraging the Polymorphism of the Merozoite Surface Protein 2 (MSP2) to Engineer Molecular Tools for Predicting Malaria Episodes in a Community.International journal of molecular sciences · 2025Article
- Beyond Tradition: Exploring Cutting-Edge Approaches for Accurate Diagnosis of Human Filariasis.Pathogens (Basel, Switzerland) · 2024Review
- Identification and Characterization ofPathogens (Basel, Switzerland) · 2024Article
- Article
- Immunoinformatics Design and Assessment of a Multiepitope Antigen (OvMCBL02) for Onchocerciasis Diagnosis and Monitoring.Diagnostics (Basel, Switzerland) · 2022Article
- Tandem Use of OvMANE1 and Ov-16 ELISA Tests Increases the Sensitivity for the Diagnosis of Human Onchocerciasis.Life (Basel, Switzerland) · 2021Article
- Computational Design and Preliminary Serological Analysis of a Novel Multi-Epitope Vaccine Candidate against Onchocerciasis and Related Filarial Diseases.Pathogens (Basel, Switzerland) · 2021Article
- The Functional Parasitic Worm Secretome: Mapping the Place ofPathogens (Basel, Switzerland) · 2020Review
- Entomological Assessment ofPathogens (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
Abstract
The public health goal of onchocerciasis in Africa has advanced from control to elimination. In this light, accurate diagnosis is necessary to determine treatment endpoints and confirm elimination, as well as to conduct surveillance for the identification of any possible recrudescence of the disease. Currently, the monitoring of onchocerciasis elimination relies on the Ov-16 test. However, this test is unable to discriminate between past and active infections. Furthermore, about 15-25% of infected persons are reported to be negative for the Ov-16 test, giving a misleading sense of security to false-negative individuals who might continue to serve as reservoirs for infections. Therefore, we opted to design and validate a more sensitive and specific chimeric antigen (OvMANE1) for onchocerciasis diagnosis, using previously reported immunodominant peptides of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.